Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

VirBiotechnology news

Latest news

Show more
Frances Wang 2025 Aug 19, 16:00

Crypto market today: BTC, ETH, BNB, SOL, DOGE, ADA, LINK, HYPE, XLM

Cryptocurrencies
Noah Lee 2025 Aug 19, 00:00

India's Russia Oil Trade & US Response: An In-Depth Analysis

Canada employment data
Tommy Yap 2025 Aug 18, 21:00

Morning Note: Canada CPI in Focus; Dollar Rises; Nikkei Pauses

Morning Note Forex Stocks Economic Data Central Banks
Frances Wang 2025 Aug 18, 16:00

Crypto news today: XRP price falls to $3.01, DOGE price hovers near $0.22

Cryptocurrencies
Tommy Yap 2025 Aug 17, 21:00

Morning Note: Gold Near Lows, Yen Strengthens, Oil Extends Losses

Morning Note Oil Gold Fed JPY
Ghko B 2025 Aug 17, 16:00

Trump family-backed crypto updates: World Liberty Financial Eyes $1.5B Raise

Cryptocurrencies
Frances Wang 2025 Aug 17, 16:00

CRWV stock is trending: what’s going on with CoreWeave Inc?

Stocks
Frances Wang 2025 Aug 17, 16:00

Crypto news today: What is the current situation of the crypto market?

Cryptocurrencies

Info

Spread

0.03

Spread (%)

0.6912 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Wednesday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Thursday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

622343680

Shares Outstanding

138916000

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-4.01

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Markets.com Bonus Trading

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Trustpilot